Harmony Biosciences Holdings, Inc. 8-K

What Happened
Harmony Biosciences Holdings, Inc. filed a Form 8‑K on January 12, 2026, announcing preliminary unaudited net product revenue for the fourth quarter and full year ended December 31, 2025. The company also provided guidance for 2026 net product revenue and an update on its clinical programs in a press release (Exhibit 99.1). Separately, Harmony will present at the 44th Annual JP Morgan Healthcare Conference on January 13, 2026; the presentation is included as Exhibit 99.2. The filings are furnished (not “filed”) and include the company’s customary forward‑looking statements and risk disclaimers.

Key Details

• Filing date: January 12, 2026 (Form 8‑K Items 2.02 and 7.01).
• Announced: preliminary unaudited net product revenue for Q4 and year ended Dec 31, 2025; provided 2026 net product revenue guidance and clinical program updates (details in attached press release).
• Investor event: presentation at the JP Morgan Healthcare Conference on January 13, 2026 (Exhibit 99.2).
• Legal/filing note: Exhibits 99.1 and 99.2 are furnished, not filed; forward‑looking statements subject to risks described in prior SEC filings. Signed by CFO Sandip Kapadia.

Why It Matters
Revenue results and 2026 guidance are primary drivers for short‑term investor expectations and analyst models; investors should review the attached press release and JP Morgan presentation for the specific revenue figures, margin context, and management commentary. The furnished (not filed) status limits certain legal exposures but does not change the economic impact of the reported figures or guidance.